Chapter 354 Autoimmune Hepatitis
Chronic hepatitis can also be caused by persistent viral infection (Chapter 350), drugs (Chapter 355), metabolic diseases (Chapter 353), or unknown and autoimmune disorders (Table 354-1). Approximately 15-20% of chronic cases are associated with hepatitis B infection; unusually severe disease may be caused by superimposed infection with hepatitis D (a defective RNA virus that is dependent on replicating hepatitis B virus [HBV]). More than 90% of hepatitis B infections in the 1st yr of life become chronic, compared with 5-10% among older children and adults. Chronic hepatitis develops in >50% of acute hepatitis C virus infections. Patients receiving blood products or who have had massive transfusions are at increased risk. Hepatitis A or E viruses do not cause chronic hepatitis. Drugs that are commonly used in children and can cause chronic liver injury include isoniazid, methyldopa, pemoline, nitrofurantoin, dantrolene, minocycline, pemoline, and the sulfonamides. Metabolic diseases can lead to chronic hepatitis including α1-antitrypsin deficiency, inborn errors of bile acid biosynthesis, and Wilson disease. Nonalcoholic steatohepatitis, usually associated with obesity and insulin resistance, is another common cause of chronic hepatitis; it is relatively benign and responds to weight reduction and/or vitamin E therapy. Progression to cirrhosis has been described in adults and some children. In most cases, the cause of chronic hepatitis is unknown; in many, an autoimmune mechanism is suggested by the finding of serum antinuclear and anti–smooth muscle antibodies and by multisystem involvement (arthropathy, thyroiditis, rashes, Coombs-positive hemolytic anemia).
Autoimmune hepatitis is a clinical constellation that suggests an immune-mediated process; it is responsive to immunosuppressive therapy (Table 354-2). Autoimmune hepatitis typically refers to a primarily hepatocyte-specific process, whereas autoimmune cholangiopathy and sclerosing cholangitis are predominated by intra- and extrahepatic bile duct injury. Overlap of the process involving both hepatocyte and bile duct directed injury may be common in children. De novo hepatitis is seen in a subset of liver transplant recipients whose initial disease was not autoimmune.
VARIABLE | TYPE 1 AUTOIMMUNE HEPATITIS | TYPE 2 AUTOIMMUNE HEPATITIS |
---|---|---|
Characteristic autoantibodies | Antinuclear antibody* | Antibody against liver-kidney microsome 1* |
Smooth-muscle antibody* | ||
Antiactin antibody† | Antibody against liver cytosol 1* | |
Autoantibodies against soluble liver antigen and liver-pancreas antigen‡ | ||
Atypical perinuclear antineutrophil cytoplasmic antibody | ||
Geographic variation | Worldwide | Worldwide; rare in North America |
Age at presentation | Any age | Predominantly childhood and young adulthood |
Sex of patients | Female in ~75% of cases | Female in ~95% of cases |
Association with other autoimmune diseases | Common | Common§ |
Clinical severity | Broad range | Generally severe |
Histopathologic features at presentation | Broad range | Generally advanced |
Treatment failure |